Use of a nonselective endothelin receptor antagonist in idiopathic pulmonary hypertension


如何引用文章

全文:

详细

Idiopathic (primary) pulmonary hypertension (IPH) is a rare disease of unknown etiology, which is characterized by elevated pulmonary artery pressure, increased total pulmonary vascular resistance, frequently a malignant course with evolving right ventricular decompensation, and a fatal outcome. The diagnosis of IPH is established on the increments in the mean resting and exercise pulmonary artery trunk pressure by more than 25 and more than 30 mm Hg at rest and during exercise, respectively, with a normal pulmonary artery wedge pressure.
Endothelin receptor antagonists (ERA) are one of the effective classes of drugs for the treatment of patients with IPH. Bosentan is the first drug from the ERA class that blocks the receptors of both types and that has been recommended by the WHO to treat patients with functional class II-IV pulmonary hypertension.
The described case demonstrates the possibility of concomitantly using bosentan in a female patient with IPH shortly after ineffective treatment with a calcium antagonist.

作者简介

Ol'ga Arkhipova

Tamila Martynyuk

Valentina Lazutkina

Dil'bar Ataullakhanova

Ol'ga Stukalova

Nikolay Danilov

Lyudmila Samoylenko

Irina Chazova

O Arkhipova

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

T Martynyuk

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

V Lazutkina

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

D Ataullakhanova

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

O Stukalova

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

N Danilov

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

L Samoilenko

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

I Chazova

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

参考

  1. Беленков Ю. Н., Чазова И. Е. Первичная легочная гипертензия. М.: Нолидж; 1999.
  2. D'Alonzo G. E., Barst R. J., Ayres S. M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 1991; 115: 343-349.
  3. Диагностика и лечение легочной гипертензии: Российские рекомендации ВНОК. М.; 2007.
  4. Мартынюк Т. В., Масенко В. П., Чазова И. Е. и др. Эндотелиальная дисфункция у больных с легочной гипертензией. Кардиология 1997; 10: 25-29.
  5. Lopes A. A., Maeda N. Y., Gongalves R. C., Bydlowski S. P. Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. Am. Heart J. 2000; 139 (4): 618-623.
  6. Guidelines for the diagnosis and treatment of pulmonary hypertension. Update 2009. European society of cardiology. Eur. Heart J. 2009; 30: 2493-2537.
  7. Rubin L. J., Badesch D. B., Barst R. J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2002; 346 (12): 896-903.
  8. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2004; 351: 1425-1436.
  9. Clozel M. Endothelin receptor antagonists: current status and perspectives. J. Cardiovasc. Pharmacol. 2000; 35: S65.
  10. Channick R. N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with primary hypertension: a randomized placebo-controlled study. Lancet 2001; 358: 1119-1123.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Consilium Medicum, 2010

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##